We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
VERA Dips Despite Positive Data From IgA Nephropathy Study
Read MoreHide Full Article
Vera Therapeutics, Inc. (VERA - Free Report) announced positive top-line data from the phase IIb ORIGIN study evaluating its lead product candidate, atacicept, for treating patients with immunoglobulin A nephropathy (IgAN).
The double-blind, placebo-controlled ORIGIN study evaluated the safety and efficacy of atacicept in 116 patients with IgAN. Data from the same showed that treatment with atacicept led to a statistical significance in the 150 mg dose group with a 33% mean reduction in proteinuria from baseline at 24 weeks — the primary endpoint of the study.
The safety profile of atacicept was similar to that of placebo in IgAN patients.
Vera plans to advance the development of atacicept into a pivotal phase III study in the first half of 2023 after discussions with the FDA.
Despite the positive news, shares of Vera were down 58.5% in the after-hours trading on Tuesday, following the announcement of the news. The stock has plunged 18% in the past year compared with the industry’s decline of 17.4%.
Image Source: Zacks Investment Research
We note that IgAN is a common cause of kidney failure and has a high unmet medical need for its treatment. Several other companies are developing treatments for treating IgAN.
Alnylam Pharmaceuticals (ALNY - Free Report) is developing cemdisiran, an investigational RNAi therapeutic, targeting the C5 component of the complement pathway, for treating IgAN in collaboration with Regeneron Pharmaceuticals (REGN - Free Report) .
ALNY, in collaboration with REGN, is advancing cemdisiran for the treatment of complement-mediated diseases. Currently, Alnylam and Regeneron are planning for the phase III development of cemdisiran in IgAN.
Apart from IgAN, Vera is evaluating atacicept in the phase III COMPASS study for the treatment of lupus nephritis.
Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus.
Vera’s portfolio currently does not have any approved products. Hence, in the absence of a marketed product, successful developments of its pipeline remain in key focus for the company.
Loss per share estimates for Syndax Pharmaceuticals have narrowed 14.5% for 2023 in the past 60 days.
Earnings of Syndax Pharmaceuticals surpassed estimates in three of the trailing four quarters and met the same on the other occasion. SNDX witnessed an earnings surprise of 95.39%, on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
VERA Dips Despite Positive Data From IgA Nephropathy Study
Vera Therapeutics, Inc. (VERA - Free Report) announced positive top-line data from the phase IIb ORIGIN study evaluating its lead product candidate, atacicept, for treating patients with immunoglobulin A nephropathy (IgAN).
The double-blind, placebo-controlled ORIGIN study evaluated the safety and efficacy of atacicept in 116 patients with IgAN. Data from the same showed that treatment with atacicept led to a statistical significance in the 150 mg dose group with a 33% mean reduction in proteinuria from baseline at 24 weeks — the primary endpoint of the study.
The safety profile of atacicept was similar to that of placebo in IgAN patients.
Vera plans to advance the development of atacicept into a pivotal phase III study in the first half of 2023 after discussions with the FDA.
Despite the positive news, shares of Vera were down 58.5% in the after-hours trading on Tuesday, following the announcement of the news. The stock has plunged 18% in the past year compared with the industry’s decline of 17.4%.
Image Source: Zacks Investment Research
We note that IgAN is a common cause of kidney failure and has a high unmet medical need for its treatment. Several other companies are developing treatments for treating IgAN.
Alnylam Pharmaceuticals (ALNY - Free Report) is developing cemdisiran, an investigational RNAi therapeutic, targeting the C5 component of the complement pathway, for treating IgAN in collaboration with Regeneron Pharmaceuticals (REGN - Free Report) .
ALNY, in collaboration with REGN, is advancing cemdisiran for the treatment of complement-mediated diseases. Currently, Alnylam and Regeneron are planning for the phase III development of cemdisiran in IgAN.
Apart from IgAN, Vera is evaluating atacicept in the phase III COMPASS study for the treatment of lupus nephritis.
Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus.
Vera’s portfolio currently does not have any approved products. Hence, in the absence of a marketed product, successful developments of its pipeline remain in key focus for the company.
Zacks Rank & Stock to Consider
Vera currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Syndax Pharmaceuticals, Inc. (SNDX - Free Report) , which sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Loss per share estimates for Syndax Pharmaceuticals have narrowed 14.5% for 2023 in the past 60 days.
Earnings of Syndax Pharmaceuticals surpassed estimates in three of the trailing four quarters and met the same on the other occasion. SNDX witnessed an earnings surprise of 95.39%, on average.